Trial Profile
Phase I trial of PBT434 in patients with atypical Parkinsonian disease
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2019
Price :
$35
*
At a glance
- Drugs ATH 434 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Alterity Therapeutics
- 05 Jul 2017 According to a Prana Biotechnology media release, PBT434 is expected to begin human testing in a Phase 1 trial later in 2017.
- 01 Mar 2016 New trial record